中等收入国家季节性流感疫苗接种的辅助效益
该研究通过对六个中等收入国家的关键知情人进行定性访谈,探讨季节性流感疫苗(SIV)接种项目实施除减少疾病外的辅助效益与挑战。受访者报告了风险群体接种态度改善、部门协作加强等效益,也面临维持投资和疫苗供应不足等挑战。
要点
- SIV接种可改善风险群体接种态度并增加需求
- SIV引入促进与其他部门及媒体合作
- 维持投资和疫苗供应不足是主要挑战
核心结论
- SIV接种项目在减少疾病之外可能带来卫生系统强化等辅助效益,但也存在维持投资和供应不足等挑战。
研究设计与样本
- 对六个中等收入PIVI疫苗接种国的关键知情人进行定性数据收集。
主要发现
- 受访者报告SIV引入改善了风险群体接种态度(表现为需求增加)。
- 受访者认为SIV引入改善了与其他部门的关系及与大众媒体的合作。
- 挑战包括维持SIV项目投资,疫苗供应不总能满足接种目标,以及管理SIV接种活动。
临床怎么用
- 在中等收入国家引入SIV时,可关注风险群体需求变化及跨部门协作等辅助效益。
- 需提前规划投资可持续性和疫苗供应保障以应对挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While seasonal influenza vaccines (SIV) remain the best method to prevent influenza-associated illnesses, implementing SIV programs may benefit countries beyond disease reduction, strengthening health systems and national immunization programs, or conversely, introduce new challenges. Few studies have examined perceived impacts of SIV introduction beyond disease reduction on health systems; understanding such impacts will be particularly salient in the context of COVID-19 vaccine introduction. We collected qualitative data from key informants-Partnership for Influenza Vaccine Introduction (PIVI) contacts in six middle-income PIVI vaccine recipient countries-to understand perceptions of ancillary benefits and challenges from SIV implementation. Respondents reported benefits associated with SIV introduction, including improved attitudes to SIV among risk groups (characterized by increased demand) and perceptions that SIV introduction improved relationships with other ministries and collaboration with mass media. Challenges included sustaining investment in SIV programs, as vaccine supply did not always meet coverage goals, and managing SIV campaigns.
引用
- Ebama MS, Chu SY, Azziz-Baumgartner E, et al. Ancillary benefits of seasonal influenza vaccination in middle-income countries. Vaccine. 2021. PMID: 33714656. doi:10.1016/j.vaccine.2021.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。